<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230719058846N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-31</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of magnesium sulfate and lidocaine spray on hemodynamic changes due to laryngoscopy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of magnesium sulfate and lidocaine spray on hemodynamic changes due to laryngoscopy and Tracheal intubation - Clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71449</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Random Method : Simple 
Randomization Unit : Individual
Randomization Tool : Using random cards A and B
50 cards A and 50 cards B that have the same appearance are placed in a container without the letters in the card being visible from outside. The study subjects take a card from the inside of the container and are classified into lidocaine or magnesium sulfate depending on the selected card. The selection of the card is permutation free and the card removed will not be placed in the container again. The study subjects will not know the letters in the cards and which of the drugs they are studying. Also, the subjects in the study will not be related to each other, Blinding description: The sprays are uniformed and covered in appearance, and the performer, who is the executor of the project, and the person recording the results do not know about the substance inside them.</study_design>
      <phase>2</phase>
      <hc_freetext>Hemodynamic changes including heart rate and blood pressure and ECG changes after laryngoscopy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In one of the studied patients, 5 puffs of lidocaine 10% containing 10 mg of lidocaine is sprayed in the throat. In the next step for both groups of atracurium relaxant 0.75 mg/kg and after 3 minutes the patient will be laryngoscopy and intubation (intubation is done by expert and maximum within 15 seconds and for men tube eight and for women pipe seven with Macintosh laryngoscope blade 4 will be used after laryngoscopy to measure changes in heart rate and blood pressure and ECG changes in minutes 1, 3, 5, 7 and 10. Intervention 2: Intervention group: In one group of patients, 5 puffs of magnesium sulfate spray 20% in the enclave. In the next step for both groups of atrophorium relaxant 0.75 mg/kg and after 3 minutes the patient will be laryngoscopy and intubation (intubation is done by expert and maximum within 15 seconds and for men tube eight and for women tube seven with blade laryngoscope macintosh 4 After laryngoscopy, we measure and record changes in heart rate and blood pressure and ECG changes in minutes 1, 3, 5, 7 and 10.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The whole data is potentially shareable after making people unidentifiable.

When:
Beginning of access period 6 months after publication of results

To whom:
Researchers working in academic and scientific institutions and people working in industry

Conditions:
For other scientific and research studies
Dastva Studies and Measures
Use in medical centers

Where to obtain:
Executor of Dr. Khalaji with Email Address 
mar_k98@yahoo.com

How to obtain:
Send an email to the project's executor 
Introducing the requesting person and organization 
Explanation of the purpose of the individual or organization of access to information

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Banafsheh Mashak</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali Medical Center, Kamali St., Shohada Sq., Shahid Beheshti St., Karaj Province, Iran</address>
        <city>karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3134877179</zip>
        <telephone>+98 26 3222 2021</telephone>
        <email>mashakbanafsheh@yahoo.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Banafsheh Mashak</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali Medical Center, Kamali St., Shohada Sq., Shahid Beheshti St., Karaj Province, Iran</address>
        <city>karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3134877179</zip>
        <telephone>+98 26 3222 2021</telephone>
        <email>mashakbanafsheh@yahoo.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients aged 18 to 40 years old who are in ASA (American Society Anesthesiology) Class I,II.
BMI is in the range of 19 to 25
Have a mallampaty score of one or two</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patient dissatisfaction or withdrawal from participation in the study
2. Having sensitivity to magnesium sulfate and lidocaine
3. Being a smoker
4. Having a cold, cough and sputum
5.Have a mallampaty score of three or four
6. In terms of airway examination in the Lemon Law criteria have problem of intubation and diffusion should have.
7.If the laryngoscopy lasts longer than 15 seconds. If there is a problem during laryngoscopy and the patient has a difficult intubation.
8. Having a history of arterial hypertension, tachycardia, bradycardia and arrhythmia
9. Use of hemodynamic drugs such as indral and ...</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I97.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other intraoperative and postprocedural complications and disorders of the circulatory system, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In one of the studied patients, 5 puffs of lidocaine 10% containing 10 mg of lidocaine is sprayed in the throat. In the next step for both groups of atracurium relaxant 0.75 mg/kg and after 3 minutes the patient will be laryngoscopy and intubation (intubation is done by expert and maximum within 15 seconds and for men tube eight and for women pipe seven with Macintosh laryngoscope blade 4 will be used after laryngoscopy to measure changes in heart rate and blood pressure and ECG changes in minutes 1, 3, 5, 7 and 10</i_keyword>
      <i_keyword>Intervention group: In one group of patients, 5 puffs of magnesium sulfate spray 20% in the enclave. In the next step for both groups of atrophorium relaxant 0.75 mg/kg and after 3 minutes the patient will be laryngoscopy and intubation (intubation is done by expert and maximum within 15 seconds and for men tube eight and for women tube seven with blade laryngoscope macintosh 4 After laryngoscopy, we measure and record changes in heart rate and blood pressure and ECG changes in minutes 1, 3, 5, 7 and 10.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic and diastolic blood pressure. Timepoint: Minutes 1, 3, 5, 7 and 10 from the start of the intervention. Method of measurement: Operating Room Pressure Gauge.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Minutes 1, 3, 5, 7 and 10 from the start of the intervention. Method of measurement: Heart Rate Indicator Device in Operating Room.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Changes in ECG. Timepoint: Minutes 1, 3, 5, 7 and 10 from the start of the intervention. Method of measurement: Electrocardiogram Monitor.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-09</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>No. 5,West 3rd Alley,12 meters of Boostan St, Danesh St, Central Jannatabad, Tehran, Iran tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
